This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Evaluating the Safety and Efficacy of Inarigivir i...
Clinical trial

Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus

Read time: 2 mins
Last updated:10th Oct 2019
Identifier: NCT04059198

An open-label, Phase 2, exploratory study to examine the safety and efficacy of inarigivir in non-cirrhotic, hepatitis B treatment-naive subjects with chronic HBV infection.

Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Exploratory Study Evaluating the Safety and Antiviral Efficacy of Inarigivir Soproxil in Non-cirrhotic Treatment-Naive Subjects Infected With Chronic Hepatitis B Virus
Actual Study Start Date: October 10, 2019
Estimated Primary Completion Date: August 2022
Estimated Study Completion Date: August 2022

- Experimental:
Arm 1 - Inarigivir Soproxil Daily
- Experimental: Arm 2 - Inarigivir Soproxil 3 Times Weekly
- Experimental: Arm 3 - Inarigivir Soproxil and TAF Daily

Category Value
Date last updated at source 2019-10-16
Study type(s) Interventional
Expected enrolment 60
Study start date 2019-10-10
Estimated primary completion date 2022-08-01

View full details